In the wake of terrorist attacks, funding is increasing for life science companies engaged in virtually any area of biosecurity. Organizations that produce vaccines and antibiotics, as well as those developing therapeutics, detection systems, and diagnostics, are receiving much-needed attention from government and private sectors. Individual companies and labs, from big pharma to small start-ups, are likely to benefit from this focus on bioterrorism countermeasures, at least into the foreseeable future.

But, like anything else in these unsettled times, uncertainties abound in the biotech world. It is not at all clear that this increased attention on biosecurity will benefit the biotech industry as a whole. And no one can say whether the government's planned countermeasures for producing vaccine and stockpiling antibiotics will be sufficient to respond to any future bioterrorist attacks.

"We are likely to see a lot of financial activity related to vaccines, monoclonal antibodies, antibiotics, and antivirals," says...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?